**Table 1.** Patient characteristics

|  |  |  |
| --- | --- | --- |
|  | **COCOMO database** | **Patients** |
| **N** | 1098 | 178 |
| **Age in years, Median (IQR)** | 50.11(42.78-58.02) | 52(47-62) |
| **Gender, Male, N (%)** | 936(85.25%) | 159(89.33%) |
| **Ethnicity Caucasian, N (%)** | 946(88%) | 153(87.43%) |
| **Mode of transmission, N (%)**  **Homosexual/bisexual**  **Heterosexual**  **Other/unknown** | 774(71.07%)  235(21.58%)  89(8.11%) | 125(70.62%)  40(22.6%)  13(7.3%) |
| **CD4 Nadir, cells/mL, Median (IQR)** | 235(117.5-350) | 237(108.25-320) |
| **CD4 at ART Initiation, cells/mL, Median (IQR)** | 260(140-397.75)10(5.62%) | 271.5(132.25-359) |
| **Viral Load at ART initiation, log copies/mL, Median (IQR)** | 4.86(4.29-5.38) | 4.99(4.31-5.48) |
| **CD4 at sampling, cells/mL, Median(IQR)** | 690(520-890) | 693(550-880.75) |
| **CD8 at sampling, cells/mL, Median (IQR)** | 840(630-1190) | 808(600-1100) |
| **Viral load (<50 copies/mL), N (%)** | 19(19-20) | 19(19-20) |
| **Duration of treatment in years, median (IQR)** | x | 15(7-18) |
| **Current Treatment, 1st drug, N (%)**  **ABC**  **TDF/TAF**  **Other** | x | 63(35.39%)  105(58.99%)  10(5.62%) |
| **Current Treatment, 3rd drug, N (%)**  **NNRTI**  **PI/r**  **INSTI**  **Other** | x | 84(47.73%)  44(25%)  48(27.27%) |
| **BMI, Mean (SD)** | 24.58(22.37-27.13) | 24.7(22.1-27.3) |
| **VAT, Median (IQR)** | x | 105.6(51.58-160.38) |
| **SAT, Median (IQR)** | x | 116.85(79.5-177.73) |
| **MetS, N (%)** | x | 86(48.31%) |
| **Hypertension, N (%)** | 451(41.07%) | 86(48.31%) |
| **Central obesity, N(%)** | 574(52.28%) | 111(62.36%) |
| **Diabetes, N(%)** | 48(4.37%) | 8(4.49%) |